JP2014515821A - 腫瘍細胞を同定するためのマーカー、その方法およびキット - Google Patents

腫瘍細胞を同定するためのマーカー、その方法およびキット Download PDF

Info

Publication number
JP2014515821A
JP2014515821A JP2014501759A JP2014501759A JP2014515821A JP 2014515821 A JP2014515821 A JP 2014515821A JP 2014501759 A JP2014501759 A JP 2014501759A JP 2014501759 A JP2014501759 A JP 2014501759A JP 2014515821 A JP2014515821 A JP 2014515821A
Authority
JP
Japan
Prior art keywords
cancer
marker
combination
group
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014501759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515821A5 (https=
Inventor
バクレ，マンジャリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncostem Diagnostics (Mauritius) Pvt Ltd
Original Assignee
Oncostem Diagnostics (Mauritius) Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncostem Diagnostics (Mauritius) Pvt Ltd filed Critical Oncostem Diagnostics (Mauritius) Pvt Ltd
Publication of JP2014515821A publication Critical patent/JP2014515821A/ja
Publication of JP2014515821A5 publication Critical patent/JP2014515821A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
JP2014501759A 2011-03-27 2012-03-26 腫瘍細胞を同定するためのマーカー、その方法およびキット Pending JP2014515821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2835CH2010 2011-03-27
IN2835/CHE/2010 2011-03-27
PCT/IB2012/051427 WO2012131564A1 (en) 2011-03-27 2012-03-26 Markers for identifying tumor cells, methods and kit thereof

Publications (2)

Publication Number Publication Date
JP2014515821A true JP2014515821A (ja) 2014-07-03
JP2014515821A5 JP2014515821A5 (https=) 2015-05-07

Family

ID=46877646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501759A Pending JP2014515821A (ja) 2011-03-27 2012-03-26 腫瘍細胞を同定するためのマーカー、その方法およびキット

Country Status (8)

Country Link
US (2) US8772455B2 (https=)
EP (1) EP2691776A4 (https=)
JP (1) JP2014515821A (https=)
KR (1) KR101621036B1 (https=)
CN (1) CN103562723B (https=)
AU (1) AU2012235767B2 (https=)
SG (1) SG193630A1 (https=)
WO (1) WO2012131564A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538550A (ja) * 2015-12-02 2018-12-27 ユニベルシテ デ リモージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｍｏｇｅｓ 癌幹細胞を検出する方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938583B2 (en) 2013-03-15 2018-04-10 Varian Medical Systems, Inc. Biomarkers for radiation treatment
CN105339390A (zh) * 2013-04-29 2016-02-17 Ogd2药物 靶向o-乙酰化的gd2神经节苷脂作为针对癌症干细胞的新型治疗和诊断策略
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
US10900968B2 (en) * 2016-05-24 2021-01-26 Oncostem Pte. Ltd. Method of prognosing and predicting breast cancer recurrence, markers employed therein and kit thereof
CN106053172B (zh) * 2016-06-03 2018-10-30 浙江世纪康大医疗科技股份有限公司 一种edta抗原修复液
US10166406B2 (en) 2017-02-24 2019-01-01 Varian Medical Systems International Ag Radiation treatment planning and delivery using collision free regions
CN115429881A (zh) * 2022-09-02 2022-12-06 中国医学科学院基础医学研究所 铁螯合剂治疗β-连环蛋白活化突变的肿瘤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508895A (ja) * 2004-08-10 2008-03-27 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 乳癌の予後診断方法およびキット
JP2010535653A (ja) * 2007-08-07 2010-11-25 ザ・ボーイング・カンパニー 複合曲線を有する複合梁及び製造方法
WO2011007853A1 (ja) * 2009-07-14 2011-01-20 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080601A2 (en) * 2004-02-23 2005-09-01 Erasmus Universiteit Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
WO2007075672A2 (en) * 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
UA110315C2 (uk) * 2006-09-29 2015-12-25 Oncomed Pharm Inc Композиція та спосіб лікування раку
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508895A (ja) * 2004-08-10 2008-03-27 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 乳癌の予後診断方法およびキット
JP2010535653A (ja) * 2007-08-07 2010-11-25 ザ・ボーイング・カンパニー 複合曲線を有する複合梁及び製造方法
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
WO2011007853A1 (ja) * 2009-07-14 2011-01-20 リンク・ジェノミクス株式会社 癌特異的アイソフォームに対するモノクローナル抗体

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6015051808; Ｔｈｅ　Ｂｒｅａｓｔ Ｖｏｌ．２０，　Ｎｏ．１, 201102, Ｐａｇｅ．７８-８５ *
JPN6015051809; Ｈｉｓｔｏｌｏｇｙ　ａｎｄ　Ｈｉｓｔｏｐａｔｈｏｌｏｇｙ Ｖｏｌ．２０, 2005, Ｐａｇｅ．７９１-７９９ *
JPN6015051810; Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ａｍｅｒｉｃａｎ　Ａｓｓｏｃｉａｔｉｏｎ　ｆｏｒ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　Ａｎｎｕａｌ　Ｍｅｅｔｉｎｇ Ｖｏｌ．４７, 2006, Ｐａｇｅ．１４１　５９５ *
JPN6015051812; Ｈｉｓｔｏｐａｔｈｏｌｏｇｙ Ｖｏｌ．３６, 2000, Ｐａｇｅ．３１３-３２５ *
JPN6015051813; Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．９，　Ｎｏ．５, 2007, Ｐａｇｅ．２１４ *
JPN6015051815; Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｒｅａｔｍｅｎｔ Ｖｏｌ．４３，　Ｎｏ．２, 1997, Ｐａｇｅ．１６５-１７３ *
JPN6015051817; Ｔｏｘｉｃｏｌｏｇｙ Ｖｏｌ．２５０, 2008, Ｐａｇｅ．８２-８８ *
JPN6015051818; Ｄｒｕｇ　Ｍｅｔａｂｏｌｉｓｍ　ａｎｄ　Ｄｉｓｐｏｓｉｔｉｏｎ Ｖｏｌ．３５，　Ｎｏ．１１, 2007, Ｐａｇｅ．２０４５-２０５２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538550A (ja) * 2015-12-02 2018-12-27 ユニベルシテ デ リモージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｍｏｇｅｓ 癌幹細胞を検出する方法

Also Published As

Publication number Publication date
US8772455B2 (en) 2014-07-08
WO2012131564A1 (en) 2012-10-04
EP2691776A4 (en) 2015-04-15
CN103562723B (zh) 2017-04-26
CN103562723A (zh) 2014-02-05
EP2691776A1 (en) 2014-02-05
AU2012235767A1 (en) 2013-11-07
KR101621036B1 (ko) 2016-05-13
AU2012235767B2 (en) 2016-02-04
US20120244556A1 (en) 2012-09-27
KR20140015500A (ko) 2014-02-06
US20140295459A1 (en) 2014-10-02
SG193630A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
Buckup et al. Plectin is a regulator of prostate cancer growth and metastasis
JP2014515821A (ja) 腫瘍細胞を同定するためのマーカー、その方法およびキット
JP5767116B2 (ja) 白金に基づく治療に対する応答の予測
JP2012177706A (ja) 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
JP2016521966A (ja) 癌の予後のための組成物および方法
Kawahara et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
WO2019010429A1 (en) METHODS OF DIAGNOSING PANCREATIC CANCER
Uemura et al. Current advances in esophageal cancer proteomics
Turato et al. S quamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity
Zhao et al. Clinical significance of vimentin expression and Her‐2 status in patients with gastric carcinoma
Meril et al. Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients
Dressler et al. Proteomic analysis of the urothelial cancer landscape
Malinowsky et al. Targeted therapies in cancer-challenges and chances offered by newly developed techniques for protein analysis in clinical tissues
CN111381042B (zh) 肝细胞癌中大血管侵犯的预测方法、试剂盒及其应用
Li et al. NHP2 and PRPF4 are hub genes associated with the prognosis of colorectal cancer
CN105102986A (zh) 用于评价前列腺癌进度的分析方法、前列腺癌进度的评价方法、前列腺癌的检测方法以及检查试剂盒
Du et al. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma
Tijana et al. Chemosensitivity and survival of non-small cell lung carcinoma patients receiving neoadjuvant therapy depend on the expression of multidrug efflux transporters
HK1193648A (en) Markers for identifying tumor cells, methods and kit thereof
HK1193648B (en) Markers for identifying tumor cells, methods and kit thereof
Chiu et al. USP15 Drives NSCLC Progression and Chemoresistance, Potentially via Regulation of the U2‐Type Spliceosomal Complex
EP2602622A1 (en) Prediction of response to platinum-based therapy
KR20240060024A (ko) 뇌종양 예후 예측용 바이오마커 조성물
Deng The mechanism of ovarian cancer chemoresistance
Jain Oncoproteomics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160812